I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Melbourne, Nov 16, 2010 (ABN Newswire) - Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) announced that positive preclinical trial results were today presented at the American Heart Association's annual conference in Chicago showing that the company's proprietary allogeneic (or "off-the-shelf") stem cells can be injected simply, safely, and effectively into the coronary arteries after a heart attack to prevent heart failure.
On the basis of these results, the company will proceed with multi-center Phase 2 clinical trials of its product Revascor (TM) delivered by a simple intracoronary infusion in heart attack patients immediately after they undergo a standard angioplasty and stent procedure to open a blocked coronary artery.
The study was performed in the Department of Interventional Cardiology at the Thoraxcenter of the Erasmus University Medical Center in Rotterdam, The Netherlands, one of the world's foremost interventional cardiology centers.
The results showed that a simple intracoronary infusion of the patented Mesenchymal Precursor Cells (MPCs) increased blood vessel numbers, prevented scar formation, and significantly improved heart muscle function after a heart attack preventing heart failure.
"These are the most compelling data that I have ever seen regarding a cell therapy approach in cardiovascular disease in the public domain or in non-disclosed data reports," said the study's Principal Investigator Associate Professor Eric Duckers, Head of Molecular Cardiology at the Thoraxcenter.
In the study, 30 sheep who underwent a large anterior myocardial infarct received an infusion into the coronary arteries of either saline (10 subjects) or allogeneic MPCs, at dosages of 12.5, 25, or 37.5 million cells (7, 7, 6 subjects/group). After two months, myocardial function, as measured by ejection fraction (EF), was significantly higher in every MPC dose group than in controls, with no significant differences noted between any of the dosages. Overall, EF in MPC-treated subjects was a mean of 12 points higher than in saline-treated controls (54.4+/-1.1% vs 42.5+/-3.6%, p<0.001). Similarly, every tested dose significantly reduced left ventricular dilation, with mean end systolic volumes in MPC-treated subjects 66+/-1.0 mL compared with 98.6+/-5.1 mL in saline-treated controls (P<0.001). Moreover, in comparison to controls, every MPC dose significantly reduced scar formation and fibrosis in heart muscle (50% mean reduction, P<0.005), and significantly increased blood vessel formation (69% mean increase in capillary density and 122% mean increase in arterioles, both P<0.001).
Heart attack is the single biggest killer of Americans with approximately 7.3 million American adults having had at least one heart attack and over 1.1 million patients having a first heart attack each year. About 80% now survive the initial heart attack. Most of these patients undergo an early angioplasty of the blocked artery accompanied by implantation of a metal stent to keep the artery open long-term. However, despite this success with early survival, a significant number of the surviving patients subsequently become disabled with heart failure.
Mesoblast's product will be developed as a simple off-the-shelf therapy for use in conjunction with angioplasty and stent procedures to prevent the complication of heart failure in those surviving a major heart attack.
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
Tel: +61-3-9639-6036
Mob: +61-419-228-128
Email: julie.meldrum@mesoblast.com
http://www.mesoblast.com
Link: http://www.abnnewswire.net/media/en/docs/64187-ASX-MSB-345623.pdf
http://www.abnnewswire.net/press/en/64187/
Angioblast Systems gets US government's $1.2 mn grants for further development of adult stem cell products
Tuesday, November 09, 2010 12:00 IST
Melbourne, Australia
Regenerative medicine company, Mesoblast Limited announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) programme.
Angioblast received the maximum grant amount awarded for each of the five projects that were eligible for QTDP funding. The projects, selected jointly by the United States Treasury Department and the Department of Health and Human Services, relate to the company's adult stem cell products for congestive heart failure, heart attack, oncology, eye and diabetes indications.
"We are pleased to have received this cash award, and will use the funds to advance our objectives for product commercialization," said Mesoblast chief executive professor Silviu Itescu.
The QTDP programme was enacted as part of the Patient Protection and Affordable Care Act of 2010 to provide tax credits to eligible companies in order to encourage investments in new therapies for prevention or treatment of acute and chronic diseases. Companies, such as Angioblast Systems, that cannot currently use a tax credit were allowed to apply for a cash grant in lieu of a tax credit.
To be eligible for the program, projects had to show reasonable potential to result in new therapies to treat areas of unmet medical need, prevent, detect, or treat chronic or acute disease and conditions, or reduce long-term health care costs in the United States. Preference was given to projects that showed the greatest potential to create and sustain (directly or indirectly) high quality, high-paying jobs in the United States, and advance United States competitiveness in the fields of life, biological, and medical sciences.
"The award serves as further external recognition, in this case by the United States Government, of the strength and promise of our adult stem cell technology platform to deliver effective therapies for a range of conditions currently in great medical need," said Professor Itescu.
Mesoblast Limited is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).
http://www.pharmabiz.com/article/detnews.asp?articleid=58232§ionid=
Not sure if you have seen this small local blurb.
http://www.signonsandiego.com/news/2010/oct/28/aethlon-names-new-president/
Actually that transaction should benefit anyone buying at under $2. Remember what the price of the stock was when JB sold the $4 pipe? The private transaction to close family and friends for half of that was considered a generous gift at the time. I really do not know how much JB is concerned about the common shareholder. However, if I understand the psychology of JB and his need to looked up to, then he needs to get the stock price up to the $2 just to get the people he cares about off of his back.
OCTOBER 29, 2010, 10:10 AM
Google Ventures Invests in HomeAway
By CLAIRE CAIN MILLER
Google Ventures, the investment fund that Google started last year, is getting into vacation rentals.
Google has invested in HomeAway, the vacation rental site that has already raised nearly half a billion dollars in venture capital. Since the company did not need extra money, Google bought shares from existing shareholders.
HomeAway, which charges homeowners to list their properties for travelers to search and rent, built the company by cutting deals. It has purchased 14 smaller rental Web sites in several countries, including VRBO and VacationRentals.com in the United States.
Now, it wants to become more tech-savvy, and is looking to Google for help, said its founder and chief executive, Brian Sharples.
“Google is a product and engineering-centric company that is growing up and becoming more of a business,” he said. “HomeAway came from more of a business, deal-making culture and now we’re trying to move the company to more of an engineering and product culture.”
HomeAway, based in Austin, Tex., wants to improve its Web site and make it easier to rent vacation houses, and expand beyond Europe, the United States and South America to Asia and Australia, he said.
Google can help HomeAway because it has acquired many start-ups and had a lot of experience integrating them as well as recruiting engineers and designing Web sites, said Bill Maris, managing partner at Google Ventures. HomeAway has already started one Google tradition, weekly all-company meetings, Mr. Sharples said.
In 2008, Mr. Sharples said
HomeAway had almost $100 million in revenue and was profitable — keys to going public. But two years later, HomeAway is staying private and taking on new investors, which is also a trend at other older tech start-ups
like Facebook, Yelp and Zynga.
Google and HomeAway did not say how much money Google had invested, but Google Ventures invests about $100 million a year in about 10 companies.
It had its first money-making success this month when Ngmoco, which makes mobile games, was acquired by a Japanese videogame company, called DeNA.
Google Ventures, which is based at the company’s headquarters in Mountain View, Calif., has also opened new offices in Cambridge, Seattle and New York, and opened a start-up lab on the Google campus in California, where portfolio companies and new start-ups can work and take advantage of Google resources.
None of that would have mattered if JBI would have produced and sold fuel with a media event in a timely fashion as shareholders were led to believe would happen in short order right after the AGM.
In fact if JBI had produced as claimed on this board, it would have created a super short squeeze at least until the horde of shares became unrestricted and the financials restated. Things happen and I understand that but the stock was priced for a flawless execution and when that did not happen it went down accordingly. The talk of "bear raids" is not credible (IMHO) and makes the rest of the "lite my fire DD" look untrustworthy with no objective value. But hey, I don't mind if those tactics are used to help drive down the price because I am still buying more at these levels and nothing that is said on this board will affect the actual value of JBI as long as the concept is proven before JBI stock is used for additional financing (this board may affect the perceived value which is the current stock price but actual value will will have to wait until claims are proven or debunked).
A few years ago my cholesterol was starting to increase into the marginal range and my doctor prescribed statin drugs. After doing my own research I changed doctors finding one with a more holistic approach and started taking Niacin and made some diet changes and never filled that prescription. My research indicated that statins can cause permanent muscle loss. My over all cholesterol is much lower now and my good cholesterol is higher and my bad cholesterol & triglycerides are both lower (I also added Vitamin D3). Not telling anyone else what to do but it worked for me.
As far as ITRO goes, waiting to see how the lawsuit settlement ends. After that I may play a little on momo runs but look back and you will see that "sell on the news" has been the only way to make money here. If ITRO gives full disclosure of their finances and debt then at that time I would be able to make a decision as to if it is over or under valued. If Dr Whitney does some serious insider buying then that would get my attention but all other PR's will be sold into until the full finances are known. IMHO
If you look back a few years when ITRO was reporting, you can learn what the debt was then and from there you will have to speculate if it is higher or lower today.
The R/S without an accounting of where the company is financially caused me to be concerned about how the company values shareholders.
For a real history lesson... read these posts.
http://siliconinvestor.advfn.com/subject.aspx?subjectid=15723
http://siliconinvestor.advfn.com/subject.aspx?subjectid=13500
Mesoblast Ltd Announces Positive Results From Phase 2 Lumbar Fusion Trial
Wednesday, 20 Oct 2010 07:02pm EDT
Mesoblast Ltd announced that interim results from its Phase 2 clinical trial for minimally invasive posterior lumbar spinal fusion showed that its proprietary off-the-shelf product NeoFuse was both safe and effective. Mesoblast is currently evaluating the effectiveness and safety of NeoFuse for minimally invasive spinal fusion surgery of the cervical and lumbar spine in 60 patients randomized to receive either NeoFuse or standard therapy across two international Phase 2 trials cleared by the United States Food and Drug Administration (FDA). The interim results from the first 17 patients enrolled in the posterior lumbar interbody fusion trial were reviewed by the Data Safety Monitoring Board. No cell-related safety issues were seen, and in particular there was no evidence of ectopic bone formation or nerve root compression as have been reported to occur with alternative biologic therapies. At three months of follow-up, CT scans showed that approximately 90% per cent of patients implanted with NeoFuse had achieved successful bone bridging. Mean pain reduction scores of more than 20% compared with baseline were achieved by both treatment groups. These results extend earlier results from Mesoblast's pilot trial for posterolateral lumbar fusion at New York's Hospital for Special Surgery, where 60% of sites implanted with NeoFuse demonstrated fusion at six months compared with only 14% of sites implanted with hip autograft bone.
Angioblast Systems Inc. Stockholders Approve Acquisition By Mesoblast Ltd
Tuesday, 19 Oct 2010 07:33pm EDT
Angioblast Systems Inc. announced that its stockholders voted unanimously at a special stockholders’ meeting held October 19, 2010, in favour of becoming a wholly-owned subsidiary of Mesoblast Limited. To increase its ownership of Angioblast from 32.8% to 100%, Mesoblast will issue approximately 94.6 million Mesoblast shares to Angioblast stakeholders.
Mesoblast Ltd Announces Issue Of Ordinary Shares
Wednesday, 6 Oct 2010 01:25am EDT
Mesoblast Ltd announced the issue of 3,200,000 ordinary shares. 3,100,000 share were issued at a price of AUD1.70 per share and 100,000 shares were issued at a price of AUD2.13 per share. 3,100,000 ordinary shares were issued as approved by shareholders on September 22, 2010 and 100,000 ordinary shares issued upon the exercise of options.
Mesoblast Ltd Announces Exercise Of Options
Saturday, 11 Sep 2010 07:53pm EDT
Mesoblast Ltd announced that it has issued 60,000 ordinary shares at an issue price of AUD1.00 per share upon the exercise of options.
Mesoblast Ltd On Track For Phase 3 Bone Marrow Transplant Trial Following Positive Meeting With FDA
Sunday, 15 Aug 2010 07:42pm EDT
Mesoblast Ltd provided market guidance on its Phase 3 bone marrow transplant program following a formal meeting with the United States Food and Drug Administration (FDA). For this Phase 3 program, the patented allogeneic, or 'off-the-shelf', adult Mesenchymal Precursor Cells (MPCs) will be used under a United States FDA Orphan Drug Designation to expand unrelated donor haematopoietic stem and progenitor cell numbers for use in patients with haematologic malignancies. In the meeting with the FDA, Mesoblast proposed a Phase 3 clinical trial whose design, size, duration, and primary endpoints were based on results from the 25 patient pilot trial performed at the University of Texas MD Anderson Cancer Center. Comparable control data were obtained from both MD Anderson Cancer Center and a United States registry of 300 patients collected by the Center for International Blood and Marrow Transplant Research. The meeting was very constructive, with FDA providing the company with expected guidance on Phase 3 primary endpoints and duration of patient follow-up. As a result of the positive meeting, and to ensure full alignment on product approval requirements, Mesoblast will seek to obtain from the FDA a binding Special Protocol Assessment (SPA) prior to commencing the Phase 3 trial. The SPA provides an agreement between FDA and the Company regarding the design, including size and clinical endpoints, of pivotal trial to support an efficacy claim in a Biologic License Application (BLA).
Mesoblast Ltd Receives TGA Regulatory Approval To Commercially Manufacture Adult Stem Cell Products
Tuesday, 20 Jul 2010 08:03pm EDT
Mesoblast Ltd announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its Mesenchymal Precursor Cells (MPC) products. Under this licence, Mesoblast will now make commercially available to doctors and hospitals across Australia manufactured MPC products for a patient's own, or autologous, use in the repair and regeneration of their damaged tissues. The cells will be manufactured under an agreement between Mesoblast and the TGA licensed contractor Cell Therapies Pty Ltd.
Mesoblast Ltd Announces Exercise Of Options
Tuesday, 6 Jul 2010 05:14am EDT
Mesoblast Ltd announced the issue of 100,000 Ordinary Shares at AUD1.20 per share upon the exercise of options.
Mesoblast Ltd Announces Exercise Of Options
Wednesday, 16 Jun 2010 12:22am EDT
Mesoblast Ltd announced that it has issued 100,000 shares at $1.20 per share and 80,000 shares at $1.00 per share upon exercise of options.
Mesoblast Ltd Clears United States FDA Phase 2 Trial For Cervical Spinal Fusion
Tuesday, 18 May 2010 07:40pm EDT
Mesoblast Ltd announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin Phase 2 clinical trials of its off-the-shelf or allogeneic stem cell product NeoFuse for fusion of the cervical spine in the neck. As with all of Mesoblast's previous Investigational New Drug (IND) submissions, FDA clearance was obtained within the minimum 30 day period. Mesoblast's Phase 2 cervical fusion clinical program will compare two doses of NeoFuse versus standard of care in 36 patients requiring bony fusion at two or more levels in the cervical spine. The FDA cleared trial will recruit 24 patients at multiple sites in the United States, and 12 patients will be recruited at multiple sites in Australia. The trial objectives are to show the safety of the cells in this application, and whether fusion can occur faster and earlier than with standard of care over a six and 12 month period. As many as 200,000 fusions of the cervical spine are performed each year in the United States alone, the majority for irreversible, end-stage degenerative disc disease.
Mesoblast Ltd To Acquire Angioblast Systems Inc; Completes Capital Raising; Appoints New CEO
Tuesday, 11 May 2010 11:25pm EDT
Mesoblast Ltd announced that it will acquire Angioblast Systems, Inc. (Angioblast). The acquisition has been structured on an agreed exchange ratio of Mesoblast shares for Angioblast stock. To acquire the remaining fully diluted Angioblast stock which is not already owned by Mesoblast (approximately 67%), the Company proposes to issue an additional 94.6 million Mesoblast shares to Angioblast security holders. Additionally, Mesoblast announced it has completed a capital raising of $37 million to fund the acquisition and advance operations of the expanded Mesoblast Group. These funds comprise $24 million invested immediately and $13 million committed subject to both shareholder approval and completion of the acquisition offer. The capital was raised from United Kingdom institutional and sophisticated investors, as well as from new and existing Australian investors, at a share price of $1.70. The placement was managed by Southern Cross Equities to international investors and in conjunction with Lodge Partners to domestic investors. Angioblast stockholders will be given the election to take the acquisition consideration either as 100% Mesoblast fully paid ordinary shares or up to 15% in cash and the balance (a minimum of 85%) in Mesoblast fully paid ordinary shares. Mesoblast’s current Executive Director, Professor Silviu Itescu, has been appointed as Chief Executive Officer (CEO) and Managing Director of the Group, Mesoblast Limited. The appointment takes effect immediately.
Oct 14, 2010 (ABN Newswire) - Australian regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it is broadening the oncology applications of its ...
_____________________
23 September 2010 – Boardroom radio interview with CEO Silviu Itescu
22 September 2010 - Acquisition of US Company Ratified by Mesoblast Shareholders
22 September 2010: Results of Extraordinary General Meeting
22 September 2010 – Chairman Speech & CEO Presentation to EGM
20 September 2010 – Mesoblast Featured at International Scientific Conferences
http://mesoblast.com/
APNT should be shown as my pick (spreadsheet update error). I do hope everyone bought some :)
So anything new in the last month (must be something in those 2000 posts - lol)?
Ok - can you show me just one P2O company that started at the "concept" phase two or less years ago and is ready for a USA stack test (any USA state and it can be a private company even if their system costs over 10x to build)?
Your analogy does not hold water because "Art" is always subjective where as fuel analysis is not. The Islechem report has terms that they did not exactly define but that does not mean that it cannot be defined (as in "Art"). You choose not to believe the JBII claims that the fuel can be blended into diesel that can be sold (back to the companies who provided the high quality plastic - smart).
You can hold to your "view" but I have a different "view" and only time will tell who is correct. As I see it, JB painted a picture of progress before the AGM that did not allow for any problems (stack test, permit, URS, media event, Nasdaq). Then, when he encountered the sensor problem and the excessive off-gas problem the timeline was set back several months.
Concurrently, JBII had an auditor upgrade with restated filings while loosing OTCBB status (I think it was the shareholders who voted for an auditor change). My guess is that those who probably never even owned JBII stock filed complaints about the Facebook access as being unfair and "material", causing JB to go silent on FB changing the "open door" policy which only seems to be a problem for the same ones who were complaining about the FB postings.
Unfortunately for the stock price, the timing of all of these events also corresponded with with a huge increase of the float when restricted shares became unrestricted (not dilution as John gave back his own shares to "fund" the purchases).
The companies physical assets and potential has only improved since the AGM (no dilution, no toxic loans, stated to have enough cash to prove their P2O superior efficiencies to the "market"). Even after the cautiously restated financial, JBI Global has not backtracked on their P2O efficiencies or their cost to produce a P2O plant.
Do the current activities point to a very aggressive timeline that was not met because of unforeseen problems from a rookie CEO, or a very badly executed pump and dump where they forgot to dump and are still poring money into expanding operations?
One thing I find interesting is that those who claim that it is impossible to do what JBII is doing also enjoy pointing to competitors claiming that they are doing the same thing?
No stock run up into the shareholders meeting? Maybe that is good as expectations are set about as low as the volume traded today? It would seem shareholders are not too excited about the reduction from 86% of marketing rights of LTC to an expected 20%-30%? Like I have said before, LTC would/will be a game changing technology AFTER it is FDA approved for the ADVANCED surgeries where it has incredible benefits but how long until that happens and how much will CTGI benefit as a holding company of small percentage of a rights to market company (exclusive rights yes, but slim chance of a buy-out without owning the patents)? LTC WAS the grand slam for CTGI but now it is just a side issue. I do hope for everyone here that the carbon capture is an absolute home run but there is fierce competition in that arena where as CTGI failed to capitalize on LTC when they had FDA approval with virtually no direct competition and that was when they were a fully reporting company listed on the OTCBB,IMHO.
For you? No... short it to the ground ;) so I can get more under $.70
Thanks
My concise view of JBII since the AGM
Is that pre RS $.05 or post RS $.05? I still say they need to change to Stevia. Coke and Pepsi use it in Japan and now you can find off-brand sodas on the shelf in the USA using it and the big boys are starting to market it too. I would try it and probably buy some CELH stock if they made the "Healthy" switch.
Did you read this MSTF speculation?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53816914
Any Comments?
How about this tactic... Send everyone in California a cert with one share of MSTF and let them look up what it is worth and how the company is run for themselves. LOL
I knew this was a total "lottery ticket" when I bought a few shares and really is not even worth the time to follow but it is interesting.
MSB.AX Break out - New 52 week high. Just printed $2.39 early in the Australian market. I believe $2.41 is the all time high set a few years ago. I don't see any news driving the spike and volume is high but not excessive. The only thing I am aware of is the special shareholder meeting on the 22nd.
EDIT $2.48 just printed. This is fun :)
Ooops. You are right. It came up on CSLI google news.
Critical Solutions to Provide Counter-Mine Products and Services
Posted by George I. Seffers on 9/07/10 • Categorized as Contract Awards
Critical Solutions International Incorporated, Carrollton, Texas, was recently awarded on a $13 million urgent contract for nine vehicle mounted mine detector with mine detonation trailer sets; and 11 vehicle-mounted mine detector with mine detection trailers and accompanying handoff training, operations network training and maintainer training classes. Tank and Automotive Command, Warren, Michigan, is the contracting activity.
http://www.afcea.org/signal/signalscape/index.php/2010/09/critical-solutions-to-provide-counter-mine-products-and-services/
http://www.istockanalyst.com/article/viewiStockNews/articleid/4471613
JB has become more conservative in his communications and I think that is wise as the transformation from penny stock to Wall street appears to have happened for JBI Global and if JB plans to under-promise and over-deliver going forward, I think WE (all of us who want JB to succeed) should support him and follow suit. Ever seen a big board stock that was growing and profitable but got hammered because they did not meet analyst expectations? Let JB set the bar low and then leap way over it.
I believe this to be a very good entry point for buying (and I have been buying). PIPE investors bought at $.80 and at $4.00 and they are not here complaining. I believe before the end of this year this stock will be more than double and possibility considerably more assuming that the permit is issued and they can go into full production. There is risk but the other companies have some value so at $.70 I like the risk/reward ratio with major upside reward if JBI Global can prove the claims they have made.
Here is my version of why we are where we are today and if you are curious about the mod situation there is a sticky that explains this.
Only time will tell if JB can produce on the claims made and take JBII stock to new heights OR the P2O process proves not to be a viable business model and JBII will become valued based on the other businesses. I understand that the stack test was completed last month and we are now waiting for the results and hopefully a permit.
At this moment in time there is a good reason that the stock is priced where it is right now. It looks to me like JB was feeling like superman before the AGM and could spout out what ever thought came into his head on FB (I do not think it is fair to call them promises but more like current thoughts and plans that would change as the situation changed). He was basking in the spotlight and if he had not encountered the oxygen sensor problem and the off-gas problem, then the stock probably would have held and continued upward as long as he had received the permit and had the media event in a timely fashion. Then for the icing on the downward spiral cake, we have the E status then losing the OTCBB status along with the large number of shares becoming unrestricted. I would bet that JB is also taking the good advice from his lawyers and going silent on FB as they are now communicating though professional channels like a big board stock. This stock has been punished for talking of NASDAQ and then being delisted even though their books are now prepared to uplist to a higher exchange once they get the stock price back up into qualifying range.
We are all here to make money and you cannot argue that dropping from over $7 to under $.80 so far this year is bad for long shareholders (except maybe for those of us who were able to average down). JBI as a company has grown up (with a top firm auditing). JB appears to be also growing up (ceasing FB musings).
I think most of us can agree that JB must know right now if he has built a P2O processor that is cheaper to operate, cheaper to build and also more efficient than any current competitor. So the key questions to me right now are:
1) If JB does not believe that he has "the goods", would he be using the capital resources to build additional processors and updating the blending site while forgoing his CEO pay until after after a permit is obtained? Don't you think he would be saving cash for another venture or to line his pocket, if his P20 did not work better that competitors?
2) After all the new cautionary statements with the new audited financials, would JB stick his neck out on a limb by basically stating that the company has enough funds to get P2O into production? This is very important because the price of JBII stock ($.10 or $100) will not have any impact on the companies operations UNTIL they need to raise additional funds. If the permit happens and a reputable independent 3rd party can give a production report that will verify the efficiency claims and cost effectiveness of the system, then the media exposure should put JBII stock back to new heights and beyond as investors see the long term value IMHO.
3) Will there be other problems and delays after the permit and fuel is being produced? Yes, but with income coming in from fuel sales they will not have the impact that the stack test and permit have had on the stock price IMHO.
So ONCP investors are up the "Wind River" without a paddle (again)? When do you expect (suspect) the next RS? Isn't it about time to wash rinse and repeat?
This is one of my unknown favorite stocks. Set to be profitable this year and they do not hype it and that is not including several of the "big" possibilities like the deal with the Army, Samsung and who knows what else that could really give this high profile exposure.
Rawnoc - Thank you for sharing your DD information.
I know we have not always seen eye to eye on the best tactics for expressing our view of JBII future but rest assured we are both doing what we think is right and we both hope for the very best for our JBI Global stock.
Was that your camper parked out on the street? lol Great DD - Thanks
While it is true that a permit is expected, I am not sure that there are many here who are frontloading for a quick trade, so it may not be "baked in". The volume has dropped off scaring traders away so all you have left are the longer term believers. Some might try to trade a percentage of their shares into a spike depending on the gravity of the news and how high the stock goes.
While I am not up to the 100% confidence level that some are, I am personally about 80% convinced that this is not a scam and 70% belief that it will prove long-term to be a viable business as it will take timelier execution in the future to rebuild a strong shareholder base.
"the Turtle" needs to come out of the shell. lol
IFNNY close $5.78 I think something is up on this one.
Stevia is the up and coming no calorie sweetener king and it is natural. SUWN is the best play I know of to take advantage of this new and healthy trend.
I know this is not new info but it is DD on Itronics that I have not seen posted here before.
You will need to scroll down to the page that is marked page 07 to see Itronics name in the first link.
http://www.scribd.com/doc/36556106/Domestic
http://www.scribd.com/doc/36559747/Ribotsky
http://seekingalpha.com/article/190917-probe-into-nir-group-expanded?source=commenter